MetLife Investment Management’s Gossamer Bio GOSS Stock Holding History
Bought
Maintained
Sold
Other funds holding GOSS
KCM
VCM
AVM
OCA
SB
SL
MetLife Investment Management's GOSS Position: Q1 2026 in Review
MetLife Investment Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 85,645 shares — an estimated $266K sold.
MetLife Investment Management first reported a position in GOSS in Q2 2019 and held it in 18 quarters. The position peaked at $415K in Q3 2022. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.
- MetLife Investment Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
- MetLife Investment Management sold 85,645 Gossamer Bio shares in Q1 2026, an estimated $266K.
- MetLife Investment Management first reported a position in Gossamer Bio in Q2 2019 and held it in 18 quarters.
- MetLife Investment Management's Gossamer Bio position peaked at $415K in Q3 2022.
- 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.